- Brand names:
- Pharmaceutical Company:
- Condition/Indication: Spinal muscular atrophy (SMA)
- Meeting Date: September 2021
- Public Summary Document (PSD) September 2021 PBAC Meeting - (PDF 1.4MB)
- Public Summary Document (PSD) September 2021 PBAC Meeting - (Word 1MB)
Onasemnogene abeparvovec – September 2021
Onasemnogene abeparvovec: Solution for injection, customised based on patient weight; Zolgensma®
Last updated
24 December 2021